TP53 and B-cell chronic lymphocytic leukemia: In line with the molecular test results of TP53 mutation, immunoblotting and flow cytometry detected the highest incidence of p53 dysfunctions in chemoresistant CLL (50%), progressive CLL (23.6%), and at diagnosis (5.9%).